All 1 tracked stories fall under one category: pharma. BIMZELX is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 4 original sources on average, compared with 2.4 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Adalimumab
All 1 tracked stories fall under one category: pharma. BIMZELX is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 4 original sources on average, compared with 2.4 for the broader beat in this window. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. We currently track 1 Biotech story that mention Adalimumab, all published on February 19, 2026.
Stories tracked
1
Sources per story
4
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Adalimumab. Shared-story counts are live from our verified record — not editorial picks.
The Juvenile Idiopathic Arthritis (JIA) market is set for a decade of steady growth, projected at a 5.6% CAGR as advanced biologics from Bristol-Myers Squibb, Novartis, and UCB enter the pediatric space. With the 7MM market valued at $2.3 billion in 2025, the shift toward targeted therapies like SOTYKTU and BIMZELX is expected to redefine treatment standards for an estimated 173,000 patients by 2036.
